Cargando…
Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine...
Autores principales: | Azad, Farhan, Miranda, Clive J, Amin, Al, Hadwani, Ruhi, Gravina, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078131/ https://www.ncbi.nlm.nih.gov/pubmed/37033542 http://dx.doi.org/10.7759/cureus.35874 |
Ejemplares similares
-
Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017) -
189 Eculizumab Therapy for Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
Publicado: (2021) -
Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome
por: Jalbert, Arielle, et al.
Publicado: (2023) -
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018)